Cite
HARVARD Citation
Giles, L. et al. (n.d.). 096 Assessment of the efficacy of erenumab during the open-label treatment (13–24 weeks) of subjects with episodic migraine who failed 2–4 prior preventive treatments: results of the LIBERTY study. Journal of neurology, neurosurgery and psychiatry. p. A31. [Online].